mRNA Momentum: A Cancer Cure's Challenging Path to Profitability Jim Cramer's recent endorsement of Moderna's cancer vaccine has sent shockwaves through the financial community.
Beneath this surface lies a more complex story about innovation, investment, and the perils of overhyping scientific breakthroughs.
A Cancer Vaccine's Long Shot to Success The Phase 3 trial results announced in August have sparked excitement about Moderna's personalized mRNA cancer vaccine.